Variant in the allosteric domain of CPS1 protein associated with effectiveness of N-carbamoyl glutamate therapy in neonatal onset CPS1 deficiency
Author:
Gragnaniello Vincenza1, Gueraldi Daniela1, Puma Andrea1, Commone Anna1, Loro Christian1, Cazzorla Chiara1, Häberle Johannes2, Burlina Alberto B.1
Affiliation:
1. Division of Inherited Metabolic Diseases, Department of Diagnostic Services , University Hospital , Padua , Italy 2. Division of Metabolism and Children’s Research Center , University Children’s Hospital Zurich , Zurich , Switzerland
Abstract
Abstract
Objectives
Carbamoyl phosphate synthetase 1 (CPS1) deficiency is a severe urea cycle disorder. Patients can present with hyperammonemic coma in the first days of life. Treatment includes nitrogen scavengers, reduced protein intake and supplementation with L-arginine and/or L-citrulline. N-carbamoyl glutamate (NCG) has been hypothesized to stimulate the residual CPS1 function, although only few patients are reported.
Case presentation
We report a patient with neonatal-onset CPS1 deficiency who received NCG in association with nitrogen scavenger and L-citrulline. The patient carried the novel variants CPS1-c.2447A>G p.(Gln816Arg) and CPS1-c.4489T>C p.(Tyr1497His). The latter is localized in the C-terminal allosteric domain of the protein, and is implicated in the binding of the natural activator N-acetyl-L-glutamate. NCG therapy was effective in controlling ammonia levels, allowing to increase the protein intake.
Conclusions
Our data show that the response to NCG can be indicated based on the protein structure. We hypothesize that variants in the C-terminal domain may be responsive to NCG therapy.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference12 articles.
1. Häberle, J, Burlina, A, Chakrapani, A, Dixon, M, Karall, D, Lindner, M, et al.. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis 2019;42:1192–230. https://doi.org/10.1002/jimd.12100. 2. Rokicki, D, Pajdowska, M, Trubicka, J, Thong, MK, Ciara, E, Piekutowska-Abramczuk, D, et al.. 3-Methylglutaconic aciduria, a frequent but underrecognized finding in carbamoyl phosphate synthetase I deficiency. Clin Chim Acta 2017;471:95–100. https://doi.org/10.1016/j.cca.2017.05.023. 3. Ah Mew, N, McCarter, R, Daikhin, Y, Lichter-Konecki, U, Nissim, I, Yudkoff, M, et al.. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-l-glutamate. J Pediatr 2014;165:401–3.e3. https://doi.org/10.1016/j.jpeds.2014.04.012. 4. de Cima, S, Polo, LM, Díez-Fernández, C, Martínez, AI, Cervera, J, Fita, I, et al.. Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis. Sci Rep 2015;5:16950. https://doi.org/10.1038/srep16950. 5. Yap, S, Gougeard, N, Hart, AR, Barcelona, B, Rubio, V. N‐wcarbamoylglutamate‐responsive carbamoyl phosphate synthetase 1 (CPS1) deficiency: a patient with a novel CPS1 mutation and an experimental study on the mutation’s effects. JIMD Rep 2019;48:36–44. https://doi.org/10.1002/jmd2.12034.
|
|